Skip to content

It’s Time to Simplify Fair Balance

Abstract pathway from tangled wires and blocks to ideas and upward progress

It’s time to face an awkward question about pharma marketing. What good is fair balance if no one understands it? Tune into almost any pharmaceutical advertisement on television, and you know what to expect. The ad opens with a patient suffering from some disease or condition. They meet with a doctor, begin treatment, and suddenly life is good. Then the drug company must deliver the required risk information. “Do not take XDrug if you…” “Serious infections have occurred in…” “Tell your doctor if you experience any of the following…” “Common side effects include…” And on and on. The risks are broadcast, but are they absorbed? The patient keeps walking through the park, playing with grandkids, and smiling during dinner with friends despite warnings about dying or harming a fetus. On paper, the drug has been effectively communicated. But was it? I think there is a difference.

During a usability testing session, I uncovered something interesting. Users usually scrolled past the fair balance at the bottom of the page and abandoned it after just a few seconds. When we did a deeper dive, we found they read only the first few lines because they thought it was too complicated.

There is surprisingly little published research that directly measures what percentage of visitors to a pharma brand website actually read the full fair-balance/Important Safety Information (ISI). But the available evidence strongly suggests that visibility is not the same as readership, and placement has a major effect.

There is little evidence that consumers actually read lengthy pharma fair-balance disclosures in their entirety. Research shows that people scan rather than read most webpage content, and that moving drug-risk information away from the main page significantly reduces consumers’ ability to recall those risks.

Fair balance shouldn’t just satisfy regulators. It should inform patients.

The FDA mandates that prescription drug advertising disclose a fair balance of information about effectiveness and risk. In TV and radio ads directed at consumers, the most significant risks are conveyed in what’s known as the major statement. Recently, the FDA has increased its requirements. Its Clear, Conspicuous, and Neutral rule requires the major statement in DTC TV and radio ads to be presented clearly, conspicuously, and neutrally. The rule recently became effective on May 20th, 24, with compliance required beginning November 20th, 20. That’s progress. But we can do better. The standard shouldn’t just be: “Did we disclose the risk?” The standard should be: “Did the patient understand the risk well enough to have an informed conversation with their healthcare provider?”

What if the FDA simplified fair balance on all websites?

The problem with today’s risk communication

It’s understandable that pharma companies are gun-shy about fair balance. Legal, regulatory and medical affairs teams want to ensure that all material risks are disclosed. Nobody wants to receive an FDA enforcement letter because a risk was minimized or omitted. But the result is often risk information that sounds like a shortened package insert rather than something an average person could use to make a healthcare decision. And there’s irony in that. More risk information doesn’t necessarily lead to better patient understanding of the risks.

In fact, the FDA has studied alternative ways to present risk information because lengthy major statements could diminish consumer understanding and obscure the information that is most important for patients to know. FDA has said that risk information directed to consumers should be written in consumer-friendly language, and has encouraged sponsors to use language appropriate for the intended audience. So maybe it’s time for the industry to reassess what “good” fair balance sounds like.

What if fair balance sounded like this?

Imagine a hypothetical prescription drug called Cardiovexa, used to reduce cardiovascular risk in certain adults. The following is deliberately simplified and illustrative only. It is not proposed regulatory language for a real product.

Traditional-style risk communication

Cardiovexa may cause serious adverse reactions including severe bleeding, liver injury and allergic reactions. Do not use Cardiovexa if you have active pathological bleeding or have had a serious hypersensitivity reaction to Cardiovexa. Tell your healthcare provider about all medications you take. The most common adverse reactions include headache, nausea, dizziness and bruising.

Now imagine communicating essentially the same concepts around the questions a patient is actually likely to have.

A patient-centered version

What is the most important risk I should know about?

Cardiovexa can increase your risk of serious bleeding. In rare cases, serious bleeding can require hospitalization and may be life-threatening.

Who should not take it?

You should not take Cardiovexa if you are currently experiencing serious bleeding or if you’ve previously had a serious allergic reaction to the medication.

What symptoms should make me call my doctor right away?

Contact your healthcare provider immediately if you experience unusual or persistent bleeding, blood in your urine or stool, vomiting or coughing up blood, or signs of a serious allergic reaction.

What side effects are more common?

Some patients may experience headache, nausea, dizziness or bruising.

What should I tell my doctor before taking it?

Tell your doctor about your medical conditions and every prescription drug, over-the-counter medication and supplement you take because some medicines could increase your risk of bleeding.

Where can I learn about all of the risks?

Ask your healthcare provider or pharmacist and review the FDA-approved medication information for the complete list of warnings, precautions and side effects.

Same basic purpose. Very different communication experience. Instead of forcing patients to decode regulatory language, we organize information around what they actually want to know:

What could happen to me?

How serious is it?

How likely is it?

What should I watch for?

What should I do if it happens?

Those are actionable questions.

Numbers could make fair balance even better

There is one more chance. Whenever possible, patients should be provided understandable absolute risk information, rather than vague terms like “common”, “uncommon” or “increased risk”. How about hearing: “Approximately 3 out of every 100 patients taking this drug experienced this side effect, versus about 1 out of 100 patients taking placebo.” That doesn’t sound like “This drug may increase your risk of this side effect.” In fact, the FDA has issued guidance specifically addressing quantitative efficacy and risk information in consumer-directed promotion. Numbers won’t work for every label, and they can be misleading if used improperly. But when you have good information, it can help patients understand risk.

Stop confusing completeness with comprehension

I think this may be THE problem with how pharmaceutical companies communicate risk. We think that if we just give people MORE information, they are BETTER informed. That’s not true.

Ask anyone who’s had to sit through 15 side effects read so fast you can’t understand what they’re saying. They’ll remember none of them. But they may remember the three or four risks that matter most to them– if those are explained clearly, with instructions on what to do.

THAT is the difference. Communicating fair balance shouldn’t be about cramming as much information as possible into 30 seconds by a pharm exec. It should be about helping patients understand their benefit-risk equation. The FDA itself says benefit-and-risk communication is key to helping patients make informed decisions with their doctors.

Pharma should test comprehension, not just recall

Drug companies spend enormous resources testing advertising. Does the message resonate? Does the patient remember the brand? Does the advertisement motivate someone to ask their doctor about the medication? Here’s another metric that should matter:

Did the patient understand the risks?

Before approving consumer advertising, companies could test whether representative patients can answer a handful of questions after seeing the communication:

  • What is the most serious risk?
  • How likely is it, if that information is known?
  • What symptoms should you watch for?
  • When should you contact a healthcare professional?
  • Who shouldn’t take the drug?
  • Where can you obtain complete safety information?

If consumers can’t answer those questions, the risk communication failed—regardless of whether every required sentence appeared on the screen.

Medical, regulatory, and marketing need to solve this together

Making fair balance easier to understand doesn’t mean that marketing can eliminate awkward warnings. Far from it. It doesn’t even mean downplaying risk. It means that Medical Affairs, regulatory, legal, patient-experience and marketing teams work together to communicate scientifically accurate safety information in a way that patients can understand. That’s much more difficult than regurgitating phrases from the prescribing information. But it’s also far more useful. Key points should be retained through translation. The language itself need not.

There is also a role for AI

Generative AI has the potential to be a remarkably helpful tool for communicating risk to patients. Picture FDA-approved prescribing information as the source, with compliant outputs including: Clinical language for doctors. Plain language for patients. Large type for older adults. Spanish and other language translations. Q&A layouts. Visual risk comparisons. The underlying info stays the same. Only the communication changes. Naturally, any AI-generated drug communications would need thorough review by medical, legal, and regulatory staff. However, leveraging tech to aid comprehension should be explored.

Fair balance needs a new objective

Pharma shouldn’t argue for less disclosure. It should argue for better communication. The FDA’s movement toward clear, conspicuous, and neutral presentation is an important step. But the industry should embrace a larger principle:

Risk information should be judged not only by whether it was presented, but by whether a reasonable patient can understand what the risk means and what they should do about it.

That’s the opportunity. Simplified fair balance doesn’t mean hiding risk. It means making risk impossible to misunderstand. And if we’re serious about patients making informed decisions about their medications, comprehension—not regulatory word count—should be the ultimate measure of successful risk communication.

Topics:

Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

Leave a Reply

Send this to a friend